Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis.
The capacity of DNA to bind RNA via Watson-Crick base-pairing is fundamental to antisense oligonucleotide strategies to inhibit gene expression, and is a property that has been exploited by bioengineers in the generation of catalytic molecules such as ribozymes, ribozyme subtypes, and more recently DNAzymes. This review describes the evolution of these gene-specific agents and summarizes recent efforts to inhibit smooth muscle cell growth with these molecules as candidate therapeutic tools in restenosis.
Santiago
F S
FS
Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales, Sydney NSW 2052, Australia.
Khachigian
L M
LM
D000818:Animals; D020029:Base Pairing; D023903:Coronary Restenosis / Q000235:genetics / Q000517:prevention & control*; D004247:DNA / Q000235:genetics; D021881:DNA, Catalytic / Q000235:genetics / Q000627:therapeutic use; D004277:DNA, Single-Stranded / Q000235:genetics / Q000627:therapeutic use; D005786:Gene Expression Regulation; D018390:Gene Targeting; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000502:physiology; D009696:Nucleic Acids / Q000235:genetics*; D020319:Oligodeoxyribonucleotides, Antisense / Q000235:genetics* / Q000627:therapeutic use*; D012313:RNA / Q000235:genetics; D016337:RNA, Catalytic / Q000235:genetics / Q000627:therapeutic use
D021881:DNA, Catalytic; D004277:DNA, Single-Stranded; D009696:Nucleic Acids; D020319:Oligodeoxyribonucleotides, Antisense; D016337:RNA, Catalytic; C402582:RNA-cleaving DNA 10-23; D012313:RNA; D004247:DNA